Breast cancer chemotherapy chemotherapy regimen detailed explanation

TC chemotherapy regimen for breast cancer refers to docetaxel combined with cyclophosphamide chemotherapy regimen. 1. Docetaxel Docetaxel is a taxoid drug that exerts anti-tumor effects by interfering with mitosis of cells. It has strong anti-tumor activity and can effectively inhibit proliferation and growth of tumor cells. Docetaxel is effective, but may cause some adverse reactions, such as bone marrow suppression (Leukopenia, thrombocytopenia, etc.), allergic reactions, gastrointestinal discomfort, etc. During use, blood routine and other indicators need to be closely monitored in order to deal with adverse reactions in time. 2. Cyclophosphamide is an alkylating agent anti-tumor drug. It can cross-link with the DNA of tumor cells, resulting in tumor cell death. Cyclophosphamide is widely used, and its adverse reactions include bone marrow suppression, gastrointestinal reactions, hemorrhagic cystitis, etc. In order to prevent hemorrhagic cystitis, mesna is usually given at the same time. TC chemotherapy regimen plays an important role in the treatment of breast cancer, especially for some patients with early breast cancer. Postoperative adjuvant chemotherapy is often selected. However, the specific treatment regimen should be individualized according to the individual conditions of the patient, such as age, physical condition, tumor characteristics, etc. During chemotherapy, the medical staff will closely monitor the adverse reactions of the patient and give corresponding supportive treatment to improve the patient's tolerance and treatment effect.

At the same time, patients themselves also need to actively cooperate with treatment, pay attention to rest, reasonable diet, maintain a good mentality, etc., in order to better cope with the challenges brought by chemotherapy.